Sanegene Bio Raises $110 Million Series B to Advance RNAi Therapeutics and Delivery Platform
Sanegene Bio, a clinical‑stage biotechnology company developing innovative RNA interference (RNAi) therapeutics, has successfully closed a Series B financing round raising more than $110 million, marking a major milestone in the company’s efforts to advance its pipeline of next‑generation RNAi medicines for metabolic, cardiovascular, autoimmune and other serious diseases. The financing will accelerate Sanegene Bio’s ongoing clinical and pre‑clinical programs, support globally oriented research efforts, and expand the reach of its proprietary RNAi delivery technologies.
The Series B round attracted a broad consortium of global institutional and strategic investors, reflecting strong confidence in Sanegene Bio’s science, leadership and platform. Among the participants were Sino Biopharm, a major pharmaceuticals and healthcare group, and Eli Lilly and Company, the multinational pharmaceutical firm that made a strategic equity investment as part of its expanding commitment to RNA‑based therapeutics. Also participating were prominent investment firms including Hillhouse Capital Group, Legend Capital, Vivo Capital, Invus, SymBiosis and Lake Bleu Capital, each bringing diverse expertise and resources to help fuel Sanegene Bio’s next phase of growth.
Established investors Qiming Venture Partners, K2 Venture Partners, TF Capital, Oriza Holdings and Northern Light Venture Capital also maintained their support by participating in the financing, underscoring deep‑rooted confidence in the company’s strategic direction and scientific progress. The strength of this investor syndicate highlights the growing appeal of RNAi technology platforms that go beyond traditional therapeutic approaches and target disease mechanisms at the genetic level.
Founded in 2021, Sanegene Bio has rapidly built out its proprietary ligand‑assisted delivery platform, known as LEAD™ (Ligand and Enhancer Assisted Delivery), which is designed to enable tissue‑specific delivery of RNAi molecules to silence disease‑causing genes safely and effectively. The company operates research and development facilities in the United States and China, and its pipeline encompasses multiple clinical‑stage candidates targeting key unmet needs in autoimmune disorders, metabolic diseases, and cardiometabolic conditions. The company’s diversified portfolio reflects strategic prioritization of areas with high patient burden and significant therapeutic opportunity.
Sanegene Bio’s Series B financing comes as the broader biotech landscape renews its focus on RNA‑based medicines following years of rapid innovations in genetic therapeutics. RNAi, in particular, has emerged as a compelling modality for targeting previously undruggable genes, and advances in delivery technologies have significantly expanded its potential across tissue types. Sanegene Bio’s LEAD™ platform aims to overcome barriers that have historically limited RNAi delivery beyond the liver, positioning the company to explore new disease areas and broaden the impact of RNAi therapies on global patient populations.
The capital raised will support multiple strategic priorities, including advancing Sanegene Bio’s most advanced clinical programs toward registration studies, accelerating the development of additional candidates, and strengthening its delivery platform for broader clinical applications. This infusion of funding also enables the company to enhance manufacturing and regulatory capabilities needed for future commercialization and global trials, while continuing to build out world‑class scientific teams with expertise in RNA biology, medicinal chemistry, and translational medicine.
Sanegene Bio’s leadership has emphasized the importance of global collaboration and investor support in bridging the gap between cutting‑edge research and real‑world therapeutic impact. By partnering with a diverse group of seasoned investors and strategic pharmaceutical players, the company is positioned to leverage collective insights, infrastructure and networks to propel its mission forward.
The Series B financing represents the latest in a series of successful fundraisings for Sanegene Bio. Earlier rounds included Series A and seed investments that helped establish its foundational technologies and expand its early clinical efforts, supported by a mix of venture capital firms and strategic backers focused on innovative healthcare breakthroughs. These earlier investments laid the groundwork for the company’s current stage, where scalable clinical development and regulatory milestones are now in full focus.
With the new funding secured and a clear roadmap for advancing its RNAi portfolio, Sanegene Bio is poised to play a significant role in the next generation of genetic medicine. Its progress reflects broader momentum in RNA‑based drug development and growing industry recognition of the potential for RNAi therapeutics to address complex diseases that have long resisted traditional drug modalities. As the company scales its operations and clinical footprint, investors and partners alike will be watching closely as it moves toward later‑stage trials and expanded global presence.
